Acadia Pharmaceuticals | ACAD - Debt


Acadia Pharmaceuticals reported $56.29M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
ALKERMES USD 72.68M 293.32M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Biogen USD 6.29B 309.5M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Corcept Therapeutics USD 6.6M 2.03M Jun/2025
Cytokinetics USD 858.06M 199.93M Jun/2025
Eisai JPY 187.52B 31.58B Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Incyte USD 42.41M 5.29M Jun/2025
J&J USD 45.8B 4.97B Sep/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Prothena USD 9.08M 699K Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025